ArticleCancer immunology, immunotherapy : CII2015

CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

Takumi Kumai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.